血清可溶性ST2 NT-proBNP的联合检测在CPR患者近期临床预后的价值

doi:10.3969/j.issn.1006-6233.2018.09.014

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (1412 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the relationship between the level of growth soluble ST2(sST2), NT-proBNP in peripheral blood and the recent clinical prognosis of cardiopulmonary resuscitation (CPR) . Methods: Serum sST2 levels were measured by ELISA in 160 patients with CPR immediately, 24 hours and 48~72 hours after CPR. The patients were divided into three groups according to the time of elevation of serum sST2. Group A: Serum sST2 levels were always lower than 200ug/L immediately after CPR, 24h, 48~72h, and group B: Serum sST2 levels were continuously elevated 24 hours, 48~72 hours after CPR and always higher than 200ug/L; group C: sST2 levels were continuously elevated 24 hours, 48~72 hours after CPR, but decreased 48~72 hours after CPR. Serum NT-proBNP levels were measured at each time point. The three groups were followed up for 6 months after CPR. Results: SST2 and NT-proBNP interact (P<0.05). The mortality of patients with high expression of sST2 (>200ug/L) and high expression of NT-proBNP (>400pg/ml) was higher than that of patients with low expression of sST2 and NT-proBNP (P<0.05). The mortality of group B was significantly higher than that of group A and group C (P<0.05), and the mortality of group A was lower than that of group C, but there was no significant difference (P>0.05). Conclusion: Combined detection of serum sST2 and NT-proBNP is expected to be a good indicator for predicting the short-term prognosis of patients with CPR.

Key words： Cardiopulmonary resuscitation Soluble ST2 NT-proBNP Recent clinical prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.09.014 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I9/1459

[1] Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy induced early ST2 changes May offer long term Therapy guidance [J].Card Fail, 2013,19(12):821~828.
[2] Friedl W, Mair J, Thomas S, et al. Relatlonship between natriuretic peptide and hemodynamics in patients heart failure at rest and after ergometrie exercise[J]. Clin Chim Acta,2009,281 (12):121~126.
[3] Dieplinger B, Egger M, Haltmayer M, et al. Increased soluble ST2 predicts long term mortality in patients with stable coronary artery disease:results from the Ludwi gshafen risk and cardiovascular health study[J].Clin Chem,2014,60(3):530~540.
[4] 张文斌, 唐其柱,李金,等.半乳糖凝集素-3在心力衰竭中的研究进展[J].国际心血管病杂志,2015,42(5):320~322.
[5] Schmitz J, Owyang A, Oldham E, et al. IL-33 an interleukin-1like cytokine that signalsvia the IL-1 lreceptor related protein ST2 and induces T helper type 2 associated cytokines[J].Immunity,2005,23(5):479~490.
[6] Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical boomechanically induced and cardoprotective signaling sys tem[J].Clin Invest, 2013, 117(15):1538~1549.
[7] Januzzi JL Jr, Rehman S, Mueller T, et al. Importance of biomarkers for long term mortality prediction in acutely dyspneic patients[J]. Clin Chem,2013,56(12):1814~1821.
[8] Socrates T, Defilippi C, Reichlin T, et al. Interleukin family member ST2 and mortality in acute dyspnoea[J].Intern Med,2014,268(5):493~500.
[9] Tsuruda T, Boerrigter G, Huntley BK, et al.brain natriuretic peptide is produced in cardiac fibroblasts and induces matris metalloproteinases[J]. Cir Res,2012,91(11):1127~1134
[10] 曹志民,于海侠,檀立端,等.心脏骤停患者心肺复苏成功后利钠肽水平变化与预后关系的研究[J]中国循环杂志,2015,30(9):859~862.
[11] Bettencourt P, FerreiraA,Dias P, et al. Evaluatiorof brain natriuretic peptide in the diagnosis of heart failure[J]. Candiology, 2014, 93(1):19~25.